Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2011-10-25 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-10-25 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement between Ligand Pharmaceuticals and Merck, including details about the collaboration and license agreement and the merger agreement. There are no financial statements or detailed financial performance data included, only a description of the event and references to prior filings. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement about a material event, not a full financial report or other specific filing type.
2011-10-21 English
4 Filing
Director's Dealing
2011-10-20 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a license agreement) between the company's subsidiary and another company. There are no financial statements or detailed financial analysis present, and the document is relatively short (2888 characters). It is not an annual or quarterly report, nor an earnings release. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material event, which fits the category of Regulatory Filings (RNS).
2011-10-19 English
S-3 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Ligand Pharmaceuticals Incorporated. It is a registration statement under the Securities Act of 1933 for the offering of securities including debt securities, preferred stock, common stock, and warrants. The document includes a prospectus describing the securities to be offered, risk factors, use of proceeds, and other related information. This type of filing is related to capital raising activities and updates on financing plans rather than financial results, management changes, or governance. Therefore, it fits the category of Capital/Financing Update filings, which cover company fundraising and capital structure changes.
2011-10-14 English
4 Filing
Director's Dealing
2011-10-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.